Publications by authors named "N Weidner"
Background: Spinal cord injury results in permanent neurological impairment and disability due to the absence of spontaneous regeneration. NG101, a recombinant human antibody, neutralises the neurite growth-inhibiting protein Nogo-A, promoting neural repair and motor recovery in animal models of spinal cord injury. We aimed to evaluate the efficacy of intrathecal NG101 on recovery in patients with acute cervical traumatic spinal cord injury.
View Article and Find Full Text PDFBackground: Since the onset of the SARS-CoV-2 pandemic in late 2019, many studies suggest that actual infection rates may far exceed reported cases. Therefore, this study provides a comprehensive overview of anti-SARS-CoV-2 antibody measurements and their significance in epidemiological surveillance, especially regarding the true extent of SARS-CoV-2 infections, allowing more detailed insights into the dynamics of the pandemic.
Methods: Antibodies were measured using the Elecsys® Anti-SARS-CoV-2 assay for the nucleocapsid (N) protein and the SARS-CoV-2 IgG (sCOVG) assay for the spike (S) protein.
Background: The reported prevalence of neuropathic pain in the general population in Germany is from 6.9% to 10%. There are both medical and surgical treatment options.
View Article and Find Full Text PDFUser-centered design of a personal-use exoskeleton: a clinical investigation on the feasibility and usability of the ABLE Exoskeleton device for individuals with spinal cord injury to perform skills for home and community environments.
Front Neurosci
September 2024
Article Synopsis
- The ABLE Exoskeleton has proven safe and feasible for individuals with spinal cord injuries (SCI) during clinical testing, but its effectiveness in home and community settings has not been previously assessed.
- A user-centered design process was utilized to evaluate the ABLE Exoskeleton's capability for performing essential tasks in everyday environments and to gather feedback for developing a personal-use version.
- The study involved 10 SCI participants undergoing a training program, revealing that while some experienced minor device-related issues, most achieved increased independence and were able to don and doff the device with minimal assistance.
Unlabelled: The EORTC 22922/10925 trial aimed to investigate the impact on overall survival (OS) of elective internal mammary and medial supraclavicular (IM-MS) radiation therapy (RT) in breast cancer stage I-III. Surgery for the primary tumour and axillary lymph nodes, chest wall RT, boost RT after whole breast RT in breast conserving therapy (BCT), RT to operated axilla, and systemic therapy were per physician's preference. The aim of the current analysis is to assess breast cancer outcomes according to different locoregional and systemic therapy used in the trial.
View Article and Find Full Text PDF